Sunday 18 October 2026
Export SABS’s income statement to Excel — free account
SAB Biotherapeutics, Inc.
SABS Healthcare Biotechnology
SAB Biotherapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.3 million, down 40.9% from fiscal 2023. In the quarter to June 2026, revenue fell 91.0%, EPS grew 74.3%, free cash flow fell 59.8% and total debt fell 5.01%, each against the same quarter a year earlier.
2.53
0.06
−2.32%
Follow SABS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
10.33 | 9.13 | 11.06 | 8.93 | |
Current Ratio |
10.50 | 9.46 | 11.45 | 9.22 | |
Net Debt/EBITDA |
9.00 | 6.21 | 5.42 | 4.42 | |
Debt/Assets |
1.72% | 1.81% | 1.24% | 1.28% | |
Debt/Equity |
0.02 | 0.02 | 0.01 | 0.01 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
(2.44) | (1.18) | 0.76 | 0.44 | |
Capex/Depreciation |
0.00 | (1.28) | (1.29) | (1.92) | |
Interest Coverage |
(292.82) | (247.18) | (318.94) | (377.05) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.22) | (0.87) | (0.27) | (0.12) | |
Capex per Share |
0.00 | (0.05) | (0.02) | (0.02) | |
Free Cash Flow per Share |
(1.22) | (0.92) | (0.28) | (0.14) | |
Cash per Share |
10.40 | 5.00 | 2.01 | 1.29 | |
Shareholders Equity per Share |
15.48 | 7.84 | 4.24 | 2.69 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
15.48 | 7.84 | 4.24 | 2.69 | |
Free Cash Flow |
(13.05) | (17.71) | (15.25) | (11.43) | |
Working Capital |
102.48 | 90.37 | 102.93 | 96.23 | |
Capital Expenditures |
0.00 | (0.93) | (0.98) | (1.58) | |
Net Current Asset Value |
94.90 | 79.74 | 91.56 | 84.51 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.39 | 0.52 | 0.81 | 0.93 | |
Average Payables |
2.13 | 2.42 | 3.03 | 3.24 | |
Average Assets |
118.62 | 108.50 | 143.30 | 134.17 | |
Average Common Equity |
100.99 | 88.73 | 124.33 | 113.40 |
Columns are period end dates